New trial results on pazopanib have important implications for patients with advanced renal cell carcinoma
COMPARZ, INTORSECT & INTORACT - Three phase III studies investigating treatments of renal cell carcinoma reported at ESMO 2012
Successes and failures: Do targeted therapies live up to their promise?
ESMO teamed up with the European Association for Cancer Research (EACR) for a joint symposium to explore recent progress in the development of targeted therapies in oncology. The session provided a brief snapshot of just a few novel results in this exciting landscape.
First results of TURANDOT Trial
Comparing two bevacizumab-containing regimens as first-line therapy for HER2 negative metastatic breast cancer
Continuation of bevacizumab beyond progression improves outcome in patients with metastatic colorectal cancer
Results of the randomized BEBYP study
New weapons in the fight against cancer
The increase in our knowledge and understanding of molecular pathways is leading to the identification of novel and appealing targets in oncology
PHARE trial results comparing 6 to 12 months of adjuvant trastuzumab in early breast cancer
New findings pose a question on optimal duration of trastuzumab therapy for women with HER2-positive early breast cancer; the subset analysis may give an answer
PM01183: A promising new drug for ovarian cancer
In platinum resistant/ refractory ovarian cancer PM01183 (lurbinectedin) produced an overall response rate of 27%, reported the results of a phase 2 trial presented in the proffered papers session for gynaecological cancers at ESMO 2012 in Vienna.
A step forward in personalised medicine in breast cancer
Two studies in yesterday’s proffered papers session explored use of DNA microarrays and surgery in breast cancer
How to hunt for a primary tumour site
An educational session explored a range of options that clinicians could adopt to manage cancer patients where the primary tumour site is unknown.